Located in Boston and the surrounding communities, Dana-Farber Cancer Institute is a leader in life changing breakthroughs in cancer research and patient care. We are united in our mission of conquering cancer, HIV/AIDS and related diseases. We strive to create an inclusive, diverse, and equitable environment where we provide compassionate and comprehensive care to patients of all backgrounds, and design programs to promote public health particularly among high-risk and underserved populations. We conduct groundbreaking research that advances treatment, we educate tomorrow's physician/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
The Beltran Lab in Dana-Farber Cancer Institute fosters aÂsupportiveÂenvironment offering excellent scope for professional growth. We provide robust mentorship for those on an academic track to pursue higher education. We also have numerous collaborations with pharmaceutical companies which provides networking opportunities and the ability to gain transferable skillsets for industry positions.
Â
The Beltran Lab is focused on understanding mechanisms of treatment resistance in advanced prostate cancer through integration of clinical and molecular features of patients combined with preclinical modeling. We have used genomics and epigenomics to elucidate the molecular mechanisms driving lineage plasticity and evolution towards an androgen indifferent state. We are developing tissue and circulating biomarkers and novel therapeutic strategies for clinical translation. Our mission is to make discoveries that improve the way we manage and treat patients with advanced prostate cancer:ÂÂhttps://beltranlab.dana-farber.org/Â
We utilize a variety of molecular biology and genomic and epigenomic approaches to understand prostate cancer disease progression, therapy resistance, and tumor heterogeneity both in patients and in preclinical models. We are particularly focused on the emerging subset of advanced prostate cancers that lose androgen receptor dependence as a mechanism of treatment resistance, associated with lineage plasticity and a change in clinical and pathologic characteristics towards a small cell/neuroendocrine phenotype. ÂCurrent projects include: 1) Defining and validating the essential genes during neuroendocrine prostate cancer progression using genome-scale CRISPR-Cas9 screening approaches to identify novel therapeutic targets; 2) Understanding the genetic, epigenetic, and phenotypic changes that drive cancer progression through bulk and single cell molecular analyses of tumor biopsies and patient-derived models; 3) Elucidating the mechanism, timing, and cooperation of identified drivers including MYCN, AURKA, EZH2, RB1, and others; 4) ÂCharacterization and preclinical testing of novel epigenetic and immune -based therapeutic approaches and combination strategies to treat, revert, or prevent non-AR driven resistance. Research in the laboratory ranges from basic mechanistic investigation of cancer gene function to highly translational genomic and functional studies of patient-derived tissues from clinical trials. Team members work in a highly collaborative environment that includes laboratory investigators, clinical investigators, and computational biologists. We are seeking an enthusiastic, dedicated, and hardworking post-doctoral scientist to join our team. The successful candidate will have a strong interest in cancer biology and therapeutics with experience in molecular biology, biochemistry, genetics/genomics or biochemistry.
At Dana-Farber Cancer Institute, we work every day to create an innovative, caring, and inclusive environment where every patient, family, and staff member feels they belong. As relentless as we are in our mission to reduce the burden of cancer for all, we are equally committed to diversifying our faculty and staff. Cancer knows no boundaries and when it comes to hiring the most dedicated and diverse professionals, neither do we. If working in this kind of organization inspires you, we encourage you to apply.Â
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other characteristics protected by law.